
Many patients with zzso breast cancer receive several types of chemotherapy, although it is recognized that there is a declining probability of zzso A major problem confronts zzso in deciding when to recommend to patients that no further chemotherapy should be zzso To address this problem we have assessed zzso zzso quality of life zzso and costs of health care for 35 patients with zzso breast cancer receiving third line chemotherapy in a representative clinical zzso zzso and utilities were measured zzso using the zzso zzso questionnaire and the time zzso zzso Patients received a median of 2 cycles of chemotherapy and lived a median of zzso zzso Twelve patients zzso had substantial zzso 10 points) improvement in the Global zzso zzso and more than zzso of patients had similar changes in emotional and social zzso The median baseline utility score was zzso and utilities correlated poorly with zzso zzso zzso patients had measurable disease and one patients experienced a partial zzso Grade 3/4 toxicity occurred in zzso of zzso The average cost of management from study entry to death was zzso zzso zzso zzso zzso Sixteen percent of this cost was associated directly with chemotherapy while hospital admissions and zzso visits accounted for 50% and zzso of the total cost zzso We conclude that: zzso many patients receiving third line chemotherapy maintain or improve zzso of zzso despite short survival and a low response rate: this might be due to chemotherapy, zzso effect, or a shift in frame of reference for zzso zzso patients were unwilling to trade quantity for quality of life; and zzso response rates and survival may be overestimated in patients selected for clinical zzso 

